Healthcare
Live Price
Offline$6.19
+0.00% today
1Y Change
-11.64%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nxera Pharma Co., Ltd. (SOLTF) is a Healthcare stock with a market cap of $86.15B and listed on OTC. The stock last traded around $6.18 and down 11.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +2.8%, EPS growth of -158.8%, a dividend yield of 0.0%. What stands out right now is revenue +2.8%, EPS -158.8%, free cash flow +66.3% with operating margin -6.6% and ROIC -1.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SOLTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOLTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SOLTF Max Drawdown
-31.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SOLTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.7B
+13.8% YoY
FY Net Income
$1.0B
+166.2% YoY
Free Cash Flow
$6.9B
-28.6% YoY
Revenue Growth
+2.8%
EPS Growth
-158.8%
Gross Margin
77.5%
Net Margin
-29.1%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 29.6B | 28.8B | 12.8B | 15.6B | 17.7B |
| Gross Profit | 21.4B | 21.2B | 9.7B | 14.6B | 16.8B |
| Operating Income | -8.3B | -5.4B | -9.5B | 3.4B | 3.8B |
| EBITDA | -3.9B | 105M | -5.7B | 3.2B | 8.2B |
| Net Income | -12.5B | -4.8B | -7.2B | 382M | 1.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.4B | 32.3B | 49.1B | 66.6B | 60.1B |
| Total Assets | 134.9B | 151.5B | 157.2B | 99.4B | 97.0B |
| Total Liabilities | 73.9B | 83.0B | 90.4B | 41.5B | 39.5B |
| Shareholder Equity | 61.1B | 68.5B | 66.8B | 57.9B | 57.5B |
| Total Debt | 60.9B | 67.9B | 74.0B | 29.7B | 29.3B |
| Net Debt | 40.6B | 35.6B | 24.9B | -36.8B | -30.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7.1B
-28.7% YoY
Capital Expenditures
201M
+33.7% YoY
Free Cash Flow
6.9B
-28.6% YoY
Key ratios
Gross Margin
77.5%
Operating Margin
-6.6%
Net Margin
-29.1%
ROE
-15.6%
Debt / Equity
0.88x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.